DHEAS LIA Assay Kit
The DHEAS LIA Assay Kit is for research use only
Size: 1×96 wells
Sensitivity: 0.02 μg/mL
Dynamic Range: 0.02–10 μg/mL
Incubation Time: 60 minutes
Sample Type: Serum
Sample Size: 25 μL
Specimen Collection and Storage for DHEAS LIA Assay
Approximately 0.1 mL of serum is required per duplicate determination. Collect 4–5 mL of blood into an appropriately labelled tube and allow it to clot. Centrifuge and carefully remove the serum layer. Store at 4°C for up to 24 hours or at -10°C or lower if the analyses are to be done at a later date. Consider all human specimens as possible biohazardous materials and take appropriate precautions when handling.
POTENTIAL BIOHAZARDOUS MATERIAL
Human serum that may be used in the preparation of the standards and controls has been tested and found to be non- reactive for Hepatitis B surface antigen and has also been tested for the presence of antibodies to HCV and Human Immunodeficiency Virus (HIV) and found to be negative. No test method however, can offer complete assurance that HIV, HCV and Hepatitis B virus or any infectious agents are absent. The reagents should be considered a potential biohazard and handled with the same precautions as applied to any blood specimen.
The principle of the following chemiluminescence immunoassay (LIA) test follows the typical competitive binding scenario. Competition occurs between an unlabelled antigen (present in standards, control and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microplate. The washing and decanting procedures remove unbound materials. After the washing step, the luminescence substrate solution is added. The relative luminescence units (RLUs) are measured on a microtiter plate luminometer. The RLU values are inversely proportional to the concentration of DHEAS in the sample. A set of calibrators are used to plot a standard curve from which the amount of DHEAS in patient samples and controls can be directly read.